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Case history 
Renal biopsy confirmed diagnosis of 
lupus nephritis class V.  Ophtalmic 
exam showed active vasculitis in both 
eyes. Clinical and diagnostic  features 
(joint pain, dacryoadenitis, retinal 
vasculitis and lupus nephritis) in 
combination with serology (positive anti-
DNA antibodies, hypocomplementemia) 
confirmed diagnosis of systemic lupus 
erythematosus. Index for activity and 
severity (BILAG and SELENA/SLEDAI) 
showed a BILAG A for 
renal/neurological/muco-cutaneous, a B 
for musculo-skeletal with  a SELENA-
SLEDAI index of 24 points.   
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Biopsy results  
A 26-year-old African female  
presented initially with chronic 
dacryoadenitis, resistant to both 
topical and systemic treatment 
with short courses of antibiotics 
and corticosteroids. Screening for 
underlying systemic condition  
revealed nephrotic range 
proteinuria (2,72g/24u ).  
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Fig 2: light microscopy, silver staining : clear 
visualisation of the thickened basal membrane 
and appearance of ‘spikes’ (formation of 
perpendicular projections of material similar to 
the glomerular basement membrane (GBM) in 
the external part of this one (between  
podocyte cytoplasm and GBM) 
   
Fig 1: light microscopy: PAS 
staining: normal structure of 
the glomeruli, no proliferation, 
thickening of the basal 
membrane due to subepithelial 
immune deposits 
 
Management and 
outcome  
Treatment was immediately initiated 
with glucocorticosteroids (GCS), 
mycophenolate mofetil (MMF) and 
Hydroxychloroquine sulphate 
(Plaquenil®). Tacrolimus was 
associated but no effect was observed 
with the proteinuria remaining in 
nephrotic range and secondary effects 
of the glucocorticosteroids becoming 
a real concern. Patient was started on 
add-on belimumab with quasi-
immediate effect on the proteinuria, 
making it possible to reduce the dose 
of the other immunosuppressants and 
gradually stop them, even the GCS.  
 
 
 
 
   
                                                                      
 
  
Discussion  
Conclusion 
This case shows excellent results of 
belimumab in lupus nephritis with 
persistent nephrotic range proteinuria 
under conventional treatment. The 
bilateral ocular vasculitis, resistant to the 
initiated treatment, also responded to the 
initiation of belimumab but remission was 
only obtained after 6 months. Alternatives 
are scarce and mostly limited due to toxic 
effects and by failure to control disease.  
 
Whether belimumab has a role in the 
treatment of CNS lupus or active lupus 
nephritis is still unknown, since these patients 
were excluded from the BLISS trials. 
However in those trials, 267 patients had 
renal involvement and treatment in this group 
was associated with significant improvement 
in proteinuria. A phase 3 study (BLISS-LN) is 
recruiting patients with lupus nephritis since 
these post-hoc analysis of the BLISS trials 
suggest that belimumab may offer renal 
benefit in patients with SLE.  
Treatment schedule  
